Skip to content
Roboearth – Lifestyle
Author:
Apnimed, Inc.
Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea
June 10, 2026
Apnimed Appoints Experienced Pharmaceutical Executive Kevin R. Lind as Chief Executive Officer to Implement Next Phase of Growth Strategy
June 8, 2026